avacincaptad pegol (Izeray)

Indications

• geographic atrophy secondary to age-related macular degeneration

Dosage

• 2 mg, 0.1 mL of 20 mg/mL solution intravitreal injection once monthly
• for use up to 12 months

20 mg/mL in single-dose vial

Adverse effects

• most common
  • conjunctival hemorrhage (13%)
  • increased intraocular pressure (9%)
  • blurred vision (8%)
  • neovascular age-related macular degeneration (7%)
• other
  • endophthalmitis
  • retinal detachment

Mechanism of action

• complement inhibitor
  • PEGylated oligonucleotide that binds to & inhibits complement C5
  • by inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a & C5b thus decreasing membrane attack complex (MAC) formation.

More general terms

• ophthalmic agent (eyedrops)